Adapting Enhanced Supports to Improve Patient Adherence to Secondary Antibiotic Prophylaxis for Rheumatic Heart Disease (SHIELD 3 Adapt)
The goal of this clinical trial is to test the effectiveness and implementation of enhanced Secondary Antibiotic Prophylaxis (SAP) supports using a hybrid type 1 effectiveness-implementation design. The purpose is to determine whether enhanced SAP supports will increase average SAP adherence in Brazil and Timor-Leste. The study will enroll people living with Rheumatic Heart Disease (RHD) and Community Health Workers (CHWs) participating in the intervention.
The main questions it aims to answer are:
- Whether CHW-led supports delivered within the community improve mean SAP adherence at 12 months post-intervention.
- Whether the intervention demonstrates acceptability, feasibility, uptake and engagement.
Researchers will compare baseline and post-intervention SAP adherence data for the 12 months prior to and following intervention rollout to see if CHW-delivered supports increase adherence.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
The first aim will utilize a non-controlled, pre-post design to evaluate CHW-led supports delivered within the community on SAP adherence. The composition of the SAP adherence supports will be finalized prior to implementation and will be comprised of a CHW-delivered package of supports covering patient reminders, education, and connection to care. The final package will reflect solutions that are easy for CHWs to deliver, acceptable to patients and families, and well aligned with local context, resources, and cultural norms. SAP adherence for the 12 months prior to and following intervention rollout will be captured from facility-based paper records, triangulated with prophylaxis cards of individual patients and the ACT registry once it is established at both sites. At enrollment, each participant will be assigned an anonymized study ID, and demographic data will be collected along with RHD history. CHWs in a ratio of approximately 1:10 patients will be selected for training, with training delivered through a standardized, competency-based curriculum including in-person workshops, practical skill-building sessions, and supervised field practice. Ongoing mentorship will be provided throughout the training period to ensure readiness, fidelity, and confidence before CHWs deliver the intervention.
The second aim will be guided by the Integrative Behavioral Model to examine implementation outcomes and mechanisms underlying behavior change related to SAP adherence. A subset of relevant constructs from the outer and inner setting domains of the Consolidated Framework for Implementation Research will augment the IBM. Participants will include people living with RHD, CHWs, and key informants. Quantitative data collection will include program activity logs completed weekly by participating CHWs and a patient knowledge and perception survey developed locally based on the General Attitudes Towards Medication Questionnaire with additional questions capturing IBM constructs. Semi-structured qualitative interviews will follow best practices, including recording with consent, post-interview debriefing, ongoing reflexivity memoing, and maintenance of detailed memos and field notes. Interview guides informed by the IBM and selected CFIR constructs will address perspectives related to acceptability, feasibility, uptake, and engagement.
Quantitative and qualitative analyses will occur in parallel. Descriptive statistics will summarize survey results and aggregate measures of patient engagement and CHW adoption. Joint displays will be constructed to visually compare qualitative and quantitative findings and examine convergence in themes or patterns. Qualitative data will be analyzed using thematic content analysis, with a codebook developed based on the IBM, CFIR, and open coding of initial interviews. All transcripts will be independently coded deductively by one study team member and reviewed by another, with disagreements resolved by consensus.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Principal Investigator, Assistant Professor
- Numer telefonu: 5136364432
- E-mail: Sarah.deLoizaga@cchmc.org
Kopia zapasowa kontaktu do badania
- Nazwa: Isabella Brigham, Bachelor of Science
- Numer telefonu: 7202808610
- E-mail: Isabella.Aspromonte@cchmc.org
Lokalizacje studiów
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45229
- Cincinnati Children's Hospital- Heart Institute
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dziecko
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Adults living with rheumatic heart disease (RHD): age ≥18 years; diagnosed with RHD; prescribed secondary antibiotic prophylaxis (SAP)
- Guardians of children living with RHD: age ≥18 years; caregiver/guardian of a child aged 5-17 years with diagnosed RHD who is prescribed SAP
- Children living with RHD: age 12-17 years; diagnosed with RHD; prescribed SAP
- Community health workers (CHWs): age ≥18 years; associated with a healthcare center providing care to patients with RHD
- Healthcare workers (HCWs): age ≥18 years; employed at a healthcare center providing care to patients with RHD; able to provide informed consent in English or the local language
Exclusion Criteria:
- Adults living with RHD: medical contraindication to SAP; inability to provide informed consent (e.g., significant cognitive or communication impairment precluding participation)
- Guardians of children living with RHD: child has a medical contraindication to SAP; inability to provide informed consent
- Children living with RHD: medical contraindication to SAP; inability to provide informed assent (e.g., significant cognitive or communication impairment precluding participation)
- Community health workers: none
- Healthcare workers: none
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Pre Intervention
Participants contribute SAP adherence data during the 12-month pre-intervention period.
Adherence will be captured from facility-based paper records, triangulated with prophylaxis cards of individual patients and the ACT registry once established.
Demographic data and RHD history will be collected at enrollment, and each participant will be assigned an anonymized study ID.
This arm reflects routine care prior to the rollout of CHW-delivered SAP adherence supports.
|
|
|
Post Intervention Period
Participants contribute SAP adherence data during the 12-month post-intervention period after implementation of a CHW-delivered package of supports.
The support package will be finalized prior to implementation and will include patient reminders, education, and connection to care.
CHWs will be trained using a standardized, competency-based curriculum including in-person workshops, practical skill-building sessions, supervised field practice, and ongoing mentorship to ensure readiness, fidelity, and confidence before delivering the intervention.
|
A CHW-delivered package of supports covering patient reminders, education, and connection to care.
The final composition of the SAP adherence supports will be finalized prior to implementation to ensure alignment with local context, resources, and cultural norms.
CHWs will be trained using a standardized, competency-based curriculum including in-person workshops, practical skill-building sessions, supervised field practice, and ongoing mentorship to ensure readiness, fidelity, and confidence before delivering the supports.
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Feasibility and acceptability of the adapted CHW-led SAP support intervention
Ramy czasowe: 24 months
|
Proportion of participants reporting the intervention as acceptable (e.g., via standardized acceptability surveys) Proportion of intended intervention components successfully implemented (fidelity/adoption) |
24 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proportion of participants achieving adequate SAP adherence
Ramy czasowe: 12 months
|
Receipt of ≥80% of scheduled secondary antibiotic prophylaxis injections
|
12 months
|
|
Participant engagement with CHW-led support components
Ramy czasowe: 2 months
|
Frequency of response to SMS reminders Participation in peer group activities Completion of scheduled CHW contacts
|
2 months
|
|
Number and type of adaptations made to the intervention
Ramy czasowe: 5 months
|
Documented modifications using human-centered design methods (e.g., interviews, co-design workshops)
|
5 months
|
|
Feasibility of intervention delivery by CHWs
Ramy czasowe: 5 months
|
Proportion of planned CHW activities completed CHW-reported ease of delivery (survey/interviews)
|
5 months
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Sarah de Loizaga, Medical Doctor, Children's Hospital Medical Center, Cincinnati
- Dyrektor Studium: Andrea Beaton, Medical Doctor, Children's Hospital Medical Center, Cincinnati
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 2026-0308
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .